Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
446.00    -1.50 (-0.34%)
Bid:
445.00
Ask:
450.00
Spread: 5.00 (1.124%)
Market Cap: £219.35m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

10 Jul 2015 07:00

RNS Number : 6817S
Zotefoams PLC
10 July 2015
 



Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update

 

 

10 July 2015 - Zotefoams, a world leader in cellular material technology, today provides a trading update for the six months ended 30 June 2015.

 

For the first six months of 2015 Zotefoams will deliver sales1 growth of approximately 8%, which is approximately 10% on a constant currency basis. Zotefoams expects revenue from MuCell Extrusion LLC, the Company's technology licensing business, to grow by around 40% and High-Performance Products ("HPP") sales growth to exceed 20%, building on the very strong HPP performance in 2014. The Company's Polyolefin foams sales volumes have increased by 6% and this is expected to deliver an increase in revenue of approximately 5%, equivalent to around 8% in constant currency. All three business units have strong forward order books.

 

The price of LDPE (Low Density Polyethylene), the Company's major raw material, was at a similar average euro price to the first half of 2014, although prices have risen sharply in recent months. The weaker euro has benefitted raw material purchases, which are significantly euro based, and US dollar sales have benefitted from the stronger dollar. However this has been more than offset by the impact of the euro on both Zotefoams' European sales and, in particular, the unhedged translational impact on the Company's balance sheet.

 

In Walton, Kentucky, USA, the major investment to increase global manufacturing capacity in support of future growth is proceeding to schedule.

 

Whilst being mindful of the potential impact of economic conditions the Company continues to expect 2015 to be another year of progress and remains confident about the long-term prospects for the business.

 

Zotefoams expects to announce its interim results for the six months ended 30 June 2015 on Tuesday 4 August 2015.

 

 

Enquiries:

Zotefoams plc

David Stirling, Group CEO

0208-664-1600

Clifford Hurst, Finance Director

FTI Consulting

0203-727-1000

Victoria Foster Mitchell/Simon Conway

 

 

Notes

 

1 Sales consolidates all external sales made by the joint-ventures as well as those made by Zotefoams plc and its subsidiaries.

2 Foreign exchange rates were:

 

H1:2015 average

H1:2014 average

30 Jun 2015

31 Dec 2014

Euro

1.378

1.223

1.412

1.289

USD

1.530

1.673

1.574

1.559

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

ZOTEK® is a registered trademark of Zotefoams plc. MuCell® is a registered trademark of Trexel Inc. T-Tubes® is a registered trademark of UFP Technologies Inc.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMGGNZLMGKZZ
Date   Source Headline
15th Aug 201312:26 pmRNSDirector/PDMR Shareholding
6th Aug 20137:00 amRNSHalf Yearly Report
12th Jul 20139:29 amRNSJoint Venture in Asia
8th Jul 20137:00 amRNSTrading Update
3rd Jun 201311:37 amRNSDirector/PDMR Shareholding
21st May 20139:43 amRNSDirector/PDMR Shareholding
15th May 201312:02 pmRNSResult of AGM
15th May 20137:00 amRNSAGM Statement and Interim Management Statement
29th Apr 20134:27 pmRNSDirector/PDMR Shareholding
10th Apr 20135:45 pmRNS2012 Annual Report and Accounts and AGM Notice
10th Apr 20132:22 pmRNSHolding(s) in Company (Replacement)
26th Mar 20131:01 pmRNSHolding(s) in Company
19th Mar 20135:43 pmRNSDirector/PDMR Shareholding
19th Mar 20135:40 pmRNSDirector/PDMR Shareholding
15th Mar 201310:00 amRNSHolding(s) in Company
12th Mar 20139:19 amRNSDirector/PDMR Shareholding
5th Mar 20137:00 amRNSFinal Results
18th Feb 20133:14 pmRNSChange of Advisers
9th Jan 20137:00 amRNSTrading Update
14th Nov 20129:56 amRNSDirector Declaration
26th Oct 20127:00 amRNSInterim Management Statement
14th Aug 201211:58 amRNSNotification of Major Interest in shares
14th Aug 20127:00 amRNSMuCell Extrusion LLC Obtains an Exclusive License
7th Aug 20127:02 amRNSHalf Yearly Report
7th Aug 20127:00 amRNSDow and MuCell Extrusion LLC Enter Agreement
9th Jul 20127:00 amRNSTrading Update
12th Jun 201212:15 pmRNSDirector/PDMR Shareholding
10th May 201212:08 pmRNSResult of AGM
10th May 20127:00 amRNSAGM and Interim Management Statement
13th Apr 201212:31 pmRNSHolding(s) in Company
13th Apr 201210:43 amRNSDirector/PDMR Shareholding
5th Apr 20123:25 pmRNSAnnual Information Update
5th Apr 201212:23 pmRNS2011 Annual Report & Accounts and Notice of AGM
5th Apr 201210:31 amRNSDirector/PDMR Shareholding
28th Mar 20128:43 amRNSHolding(s) in Company
6th Mar 20127:00 amRNSFinal Results
27th Jan 201210:57 amRNSHolding(s) in Company
19th Jan 20124:48 pmRNSHolding(s) in Company
9th Jan 20127:00 amRNSTrading Statement
13th Dec 20113:27 pmRNSDirector/PDMR Shareholding
22nd Nov 20117:00 amRNSDirector/PDMR Shareholding
28th Oct 20112:18 pmRNSHolding(s) in Company
24th Oct 20117:00 amRNSInterim Management Statement
16th Sep 20112:35 pmRNSHolding(s) in Company
2nd Aug 20117:00 amRNSHalf Yearly Report
5th Jul 20117:00 amRNSTrading Update
16th Jun 20117:00 amRNSDirectorate Appointments
7th Jun 20119:13 amRNSAnnual Information Update
13th May 20112:10 pmRNSHolding(s) in Company
13th May 201110:34 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.